OBJECTIVE: The aim of the present study was to investigate the pharmacokinetics and pharmacodynamics of low-dose methotrexate (MTX) in the early phase (3 months) after the start of antipsoriatic therapy. METHODS: Ten male and female psoriatic patients who failed to respond to previous conventional therapy were treated with 15 mg oral MTX once per week. The pharmacokinetics in plasma and the urinary excretion of MTX and 7-hydroxymethotrexate (7-OH MTX) were investigated after doses 1, 5 and 13 (corresponding to phases I, II and III, respectively). On the same occasions, MTX accumulation in erythrocytes obtained before MTX administration was investigated. Pharmacodynamics of MTX were evaluated using the psoriasis area and severity index (PASI) score. RESULTS: There were marked intersubject differences (range of coefficients of variation 34.9-76.3%) in the area under the curve (AUC), peak concentration (Cmax) and clearance (CL) of MTX. Total CL was proportional to renal clearance (CLR) (r2 = 0.735, P < 0.0001) which accounted for 73 (19)% of the former. There was a strong linear relationship (r2 = 0.819, P < 0.0001) between CL of MTX and creatinine clearance. Within 48 h of drug administration, the urinary excretion of MTX was 46-99% of the dose, while that of 7-OH MTX was 1.5-8.6%. In 8 of 10 patients, more than 70% of the MTX dose was recovered. No intraindividual variations of MTX kinetic parameters during treatment were observed. MTX concentrations in erythrocytes reached the steady-state concentration in the range 40.7-170 nmol.l(-1) after 2 months of therapy. Pharmacodynamic measurement versus pharmacokinetics revealed a significant inverse relationship between PASI score and MTX AUC (rs = -0.912, P < 0.002) and between PASI score and erythrocytic MTX (rs = -0.988, P < 0.002). CONCLUSION: The relationship between MTX pharmacokinetics (AUC or erythrocytic MTX) and pharmacodynamics (PASI score) may exist. It is likely that the efficacy of psoriasis therapy with MTX could be improved by adjusting the dose according to plasma concentrations obtained after the first MTX administration.

Department of Pharmacology Charles University Faculty of Medicine Hradec Kralove Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc14044938

003      

CZ-PrNML

005      

20161024073626.0

007      

ta

008      

140205s1998 gw f 000 0|eng||

009      

AR

024    7_

$a 10.1007/s002280050404 $2 doi

035    __

$a (PubMed)9551702

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a gw

100    1_

$a Chládek, Jaromír $7 _AN070715 $u Department of Pharmacology, Charles University, Faculty of Medicine, Hradec Kralove, Czech Republic.

245    10

$a Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment / $c J Chladek, J Martinkova, M Simkova, J Vaneckova, V Koudelkova, M Nozickova

520    9_

$a OBJECTIVE: The aim of the present study was to investigate the pharmacokinetics and pharmacodynamics of low-dose methotrexate (MTX) in the early phase (3 months) after the start of antipsoriatic therapy. METHODS: Ten male and female psoriatic patients who failed to respond to previous conventional therapy were treated with 15 mg oral MTX once per week. The pharmacokinetics in plasma and the urinary excretion of MTX and 7-hydroxymethotrexate (7-OH MTX) were investigated after doses 1, 5 and 13 (corresponding to phases I, II and III, respectively). On the same occasions, MTX accumulation in erythrocytes obtained before MTX administration was investigated. Pharmacodynamics of MTX were evaluated using the psoriasis area and severity index (PASI) score. RESULTS: There were marked intersubject differences (range of coefficients of variation 34.9-76.3%) in the area under the curve (AUC), peak concentration (Cmax) and clearance (CL) of MTX. Total CL was proportional to renal clearance (CLR) (r2 = 0.735, P < 0.0001) which accounted for 73 (19)% of the former. There was a strong linear relationship (r2 = 0.819, P < 0.0001) between CL of MTX and creatinine clearance. Within 48 h of drug administration, the urinary excretion of MTX was 46-99% of the dose, while that of 7-OH MTX was 1.5-8.6%. In 8 of 10 patients, more than 70% of the MTX dose was recovered. No intraindividual variations of MTX kinetic parameters during treatment were observed. MTX concentrations in erythrocytes reached the steady-state concentration in the range 40.7-170 nmol.l(-1) after 2 months of therapy. Pharmacodynamic measurement versus pharmacokinetics revealed a significant inverse relationship between PASI score and MTX AUC (rs = -0.912, P < 0.002) and between PASI score and erythrocytic MTX (rs = -0.988, P < 0.002). CONCLUSION: The relationship between MTX pharmacokinetics (AUC or erythrocytic MTX) and pharmacodynamics (PASI score) may exist. It is likely that the efficacy of psoriasis therapy with MTX could be improved by adjusting the dose according to plasma concentrations obtained after the first MTX administration.

590    __

$a bohemika - dle Pubmed

650    02

$a dospělí $7 D000328

650    02

$a senioři $7 D000368

650    02

$a senioři nad 80 let $7 D000369

650    02

$a dermatologické látky $x aplikace a dávkování $x farmakokinetika $x krev $x moč $7 D003879

650    02

$a ženské pohlaví $7 D005260

650    02

$a lidé $7 D006801

650    02

$a mužské pohlaví $7 D008297

650    02

$a methotrexát $x aplikace a dávkování $x farmakokinetika $x krev $x moč $7 D008727

650    02

$a lidé středního věku $7 D008875

650    12

$a psoriáza $x farmakoterapie $x krev $x moč $7 D011565

650    02

$a časové faktory $7 D013997

655    _2

$a klinické zkoušky $7 D016430

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Martínková, Jiřina, $d 1940- $7 nlk19990073537 $u Department of Pharmacology, Charles University, Faculty of Medicine, Hradec Kralove, Czech Republic

700    1_

$a Šimková, Marie $7 xx0153126

700    1_

$a Vaněčková, Jaroslava, $d 1945- $7 jn20020220009

700    1_

$a Vavřinová, Věra, $7 xx0207341 $d 1943-

700    1_

$a Nožičková, Marie, $d 1937-2016 $7 nlk19990073626

773    0_

$t European Journal of Clinical Pharmacology $x 0031-6970 $g Roč. 53, č. 6 (1998), s. 437-444 $p Eur J Clin Pharmacol $w MED00001613

910    __

$a ABA008 $b B 1318 $y 4 $z 0

990    __

$a 20140205094422 $b ABA008

991    __

$a 20161024074038 $b ABA008

999    __

$a ok $b bmc $g 1009617 $s 843470

BAS    __

$a 3

BMC    __

$a 1998 $b 53 $c 6 $d 437-444 $x MED00001613 $i 0031-6970 $m European journal of clinical pharmacology $n Eur J Clin Pharmacol

GRA    __

$a IZ2960 $p MZ0

LZP    __

$a NLK 2014-02/lpbo